476 related articles for article (PubMed ID: 30426788)
1. Respiratory syncytial virus vaccine: where are we now and what comes next?
Noor A; Krilov LR
Expert Opin Biol Ther; 2018 Dec; 18(12):1247-1256. PubMed ID: 30426788
[TBL] [Abstract][Full Text] [Related]
2. Advances in and the potential of vaccines for respiratory syncytial virus.
Jorquera PA; Oakley KE; Tripp RA
Expert Rev Respir Med; 2013 Aug; 7(4):411-27. PubMed ID: 23964629
[TBL] [Abstract][Full Text] [Related]
3. Current progress on development of respiratory syncytial virus vaccine.
Chang J
BMB Rep; 2011 Apr; 44(4):232-7. PubMed ID: 21524347
[TBL] [Abstract][Full Text] [Related]
4. The third pandemic: The respiratory syncytial virus landscape and specific considerations for the allergist/immunologist.
Frenkel LD; Gaur S; Bellanti JA
Allergy Asthma Proc; 2023 Jul; 44(4):220-228. PubMed ID: 37236777
[No Abstract] [Full Text] [Related]
5. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
[TBL] [Abstract][Full Text] [Related]
6. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
[TBL] [Abstract][Full Text] [Related]
7. Vaccines against human respiratory syncytial virus in clinical trials, where are we now?
Rossey I; Saelens X
Expert Rev Vaccines; 2019 Oct; 18(10):1053-1067. PubMed ID: 31587585
[No Abstract] [Full Text] [Related]
8. Passive and active immunization against respiratory syncytial virus for the young and old.
Villafana T; Falloon J; Griffin MP; Zhu Q; Esser MT
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525961
[TBL] [Abstract][Full Text] [Related]
9. The challenges of RSV vaccines. Where do we stand?
Fretzayas A; Moustaki M
Recent Pat Antiinfect Drug Discov; 2010 Jun; 5(2):99-107. PubMed ID: 20156180
[TBL] [Abstract][Full Text] [Related]
10. Chitosan alters inactivated respiratory syncytial virus vaccine elicited immune responses without affecting lung histopathology in mice.
Muralidharan A; Russell MS; Larocque L; Gravel C; Sauvé S; Chen Z; Li C; Chen W; Cyr T; Rosu-Myles M; Wang L; Li X
Vaccine; 2019 Jul; 37(30):4031-4039. PubMed ID: 31186190
[TBL] [Abstract][Full Text] [Related]
11. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
[TBL] [Abstract][Full Text] [Related]
12. The journey to a respiratory syncytial virus vaccine.
Mejias A; Rodríguez-Fernández R; Oliva S; Peeples ME; Ramilo O
Ann Allergy Asthma Immunol; 2020 Jul; 125(1):36-46. PubMed ID: 32217187
[TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus vaccines: an update on those in the immediate pipeline.
Esposito S; Di Pietro G
Future Microbiol; 2016 Oct; 11():1479-1490. PubMed ID: 27750448
[TBL] [Abstract][Full Text] [Related]
14. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
Shafique M; Wilschut J; de Haan A
Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195
[TBL] [Abstract][Full Text] [Related]
15. Strategic priorities for respiratory syncytial virus (RSV) vaccine development.
Anderson LJ; Dormitzer PR; Nokes DJ; Rappuoli R; Roca A; Graham BS
Vaccine; 2013 Apr; 31 Suppl 2(Suppl 2):B209-15. PubMed ID: 23598484
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with respiratory syncytial virus vaccines.
Piedra PA
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
[TBL] [Abstract][Full Text] [Related]
17. Active prophylaxis for respiratory syncytial virus: current knowledge and future perspectives.
Vittucci AC; Zangari P; Ciarlitto C; Di Camillo C; Grandin A; Cotugno N; Marchili MR; Villani A
Minerva Pediatr; 2018 Dec; 70(6):566-578. PubMed ID: 30334621
[TBL] [Abstract][Full Text] [Related]
18. Respiratory syncytial virus subunit vaccines based on the viral envelope glycoproteins intended for pregnant women and the elderly.
Beugeling M; De Zee J; Woerdenbag HJ; Frijlink HW; Wilschut JC; Hinrichs WLJ
Expert Rev Vaccines; 2019 Sep; 18(9):935-950. PubMed ID: 31446807
[No Abstract] [Full Text] [Related]
19. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
Munoz FM
Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
[TBL] [Abstract][Full Text] [Related]
20. Nucleic acid-based vaccines targeting respiratory syncytial virus: Delivering the goods.
Smith TRF; Schultheis K; Broderick KE
Hum Vaccin Immunother; 2017 Nov; 13(11):2626-2629. PubMed ID: 28881156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
